CA2095928A1 - Epreuves de diagnostic dependants des lipides - Google Patents

Epreuves de diagnostic dependants des lipides

Info

Publication number
CA2095928A1
CA2095928A1 CA2095928A CA2095928A CA2095928A1 CA 2095928 A1 CA2095928 A1 CA 2095928A1 CA 2095928 A CA2095928 A CA 2095928A CA 2095928 A CA2095928 A CA 2095928A CA 2095928 A1 CA2095928 A1 CA 2095928A1
Authority
CA
Canada
Prior art keywords
assay
phospholipid
suspension
sample
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2095928A
Other languages
English (en)
Other versions
CA2095928C (fr
Inventor
Andrew S. Janoff
Joyce Rauch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2095928A1 publication Critical patent/CA2095928A1/fr
Application granted granted Critical
Publication of CA2095928C publication Critical patent/CA2095928C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Dans une analyse dépendant des lipides permettant d'établir un diagnostic, on utilise une suspension aqueuse stable d'un phospholipide qui présente normalement une structure hexagonale (HII) lorsqu'il se trouve en dispersion dans un milieu aqueux sans détergent, ladite suspension renfermant le phospholipide, un détergent, et une phase aqueuse. Dans la suspension stable, le phospholipide reste en suspension dans des conditions de température égales à 25 C pendant au moins une heure. Ladite suspension est adaptée pour utiliser le phospholipide dans une analyse recherchant des anticoagulants lupiques, ladite analyse comprenant l'étape de pré-inscription d'un échantillon d'essai avec le phospholipide. Dans un autre aspect de l'invention, une analyse est utilisée pour déterminer si un patient possède un anticoagulant lupique, cette analyse s'effectuant comme suit: a) on recueille des premier et deuxième échantillons du plasma du patient; b) on fait incuber le premier échantillon avec la suspension de phospholipide stable et aqueuse de cette invention; c) on effectue une analyse dépendant des lipides permettant d'établir le diagnostic sur les premier et deuxième échantillons, cette analyse fournissant une indication positive lorsq'on l'utilise pour analyser un échantillon renfermant des anticoagulants lupiques; et d) on compare les résultats des analyses effectuées sur les premier et deuxième échantillons, la présence d'un résultat normal pour le premier échantillon et d'un résultat positif pour le deuxième échantillon indiquant que le patient possède un anticoagulant lupique.
CA002095928A 1990-12-07 1990-12-28 Epreuves de diagnostic dependants des lipides Expired - Fee Related CA2095928C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62334090A 1990-12-07 1990-12-07
US623,340 1990-12-07
PCT/US1990/007688 WO1992010586A1 (fr) 1990-12-07 1990-12-28 Analyses dependant des lipides permettant d'etablir un diagnostic

Publications (2)

Publication Number Publication Date
CA2095928A1 true CA2095928A1 (fr) 1992-06-08
CA2095928C CA2095928C (fr) 1999-08-31

Family

ID=24497709

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002095928A Expired - Fee Related CA2095928C (fr) 1990-12-07 1990-12-28 Epreuves de diagnostic dependants des lipides

Country Status (10)

Country Link
EP (1) EP0561780B1 (fr)
JP (1) JP2983630B2 (fr)
AT (1) ATE140798T1 (fr)
AU (1) AU648775B2 (fr)
CA (1) CA2095928C (fr)
DE (1) DE69027936T2 (fr)
DK (1) DK0561780T3 (fr)
ES (1) ES2090306T3 (fr)
GR (1) GR3021412T3 (fr)
WO (1) WO1992010586A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229933A1 (de) * 1992-09-08 1994-03-10 Max Planck Gesellschaft Verfahren zur Bestimmung von Thrombose verursachenden Lupus-anticoagulant-Antikörpern
US5472852A (en) * 1993-09-15 1995-12-05 Oklahoma Medical Research Foundation Assay for detection of selective Protein C inhibition by patients
RU2239197C1 (ru) * 2003-01-23 2004-10-27 Межрегиональная благотворительная общественная организация инвалидов "Общество больных гемофилией" Способ определения волчаночного антикоагулянта
JP4377207B2 (ja) * 2003-11-28 2009-12-02 シスメックス株式会社 血液凝固時間測定方法および血液凝固時間測定用試薬

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4543339A (en) * 1982-03-16 1985-09-24 Oneill Christopher Early pregnancy detection by detecting enhanced blood platelet activation
US4698299A (en) * 1985-02-19 1987-10-06 The Liposome Company, Inc. Lipid-dependent diagnostic assays
US4666831A (en) 1985-02-19 1987-05-19 The Liposome Company, Inc. Lipid-dependent diagnostic assays
DE3875857D1 (de) * 1987-08-13 1992-12-17 Synbiotics Corp Bestimmungen einer amphipathischen substanz durch verwendung einer lipophilen oberflaeche.
US4877741A (en) * 1988-10-24 1989-10-31 The United States Of America As Represented By The Secretary Of The Air Force Treatment of human plasma with brown recluse spider toxin to emulate a lupus anticoagulant

Also Published As

Publication number Publication date
CA2095928C (fr) 1999-08-31
ES2090306T3 (es) 1996-10-16
GR3021412T3 (en) 1997-01-31
DE69027936T2 (de) 1997-03-06
JP2983630B2 (ja) 1999-11-29
JPH06503640A (ja) 1994-04-21
AU7162091A (en) 1992-07-08
DE69027936D1 (de) 1996-08-29
ATE140798T1 (de) 1996-08-15
EP0561780A4 (fr) 1994-08-03
EP0561780B1 (fr) 1996-07-24
EP0561780A1 (fr) 1993-09-29
WO1992010586A1 (fr) 1992-06-25
AU648775B2 (en) 1994-05-05
DK0561780T3 (da) 1996-12-09

Similar Documents

Publication Publication Date Title
Levy Determination of sodium with ion-selective electrodes.
TWI256975B (en) Compositions containing a urea derivative dye for detecting an analyte and methods for using the same
Kurosaka et al. A new enzymatic assay for selectively measuring conjugated bilirubin concentration in serum with use of bilirubin oxidase
SE8008952L (sv) Forfarande och anordning for bestemning av serumlipoproteiner
BR9811406A (pt) Dispositivo para detenção da presença de pelo menos um analito em uma amostra biológica, kit para detenção da presença de pelo menos um analito em uma amostra biológica, e, processo de detecção da presença de pelo menos um analito em uma amostra biológica
AU696681B2 (en) Method for quantitatively determining cholesterol
AU9066998A (en) Use of check surfaces for identifying disturbing samples in a detection procedure
EP0030388A3 (fr) Procédé pour la détection et la détermination quantitative de sang occulté dans un échantillon humain
CA2235316A1 (fr) Procede de detection d'anticorps antipolymeres et trousse d'essai destinee au diagnostic de maladies liees aux silicones
Klein et al. Determination of brucella immunoglobulin G agglutinating antibody titer with dithiothreitol
DE3850249D1 (de) Nachweis von analyt in partikel enthaltenden proben.
CA2095928A1 (fr) Epreuves de diagnostic dependants des lipides
AU5263190A (en) Method and kit for determining tyrosine-phosphorylating and dephosphorylating activities
Elyas et al. Valproic acid estimation by enzyme immunoassay
Liu et al. Immunochemical determination of LDH-1
DE59808639D1 (de) Verfahren zur bestimmung von schilddrüsen-autoantikörpern
BenGershom Screening for albuminuria: A case for estimation of albumin in urine
Delahunty et al. Automated creatine kinase-MB estimation by immuno-inhibition: a clinical evaluation.
EP0352139A3 (fr) Détection des antigènes ou anticorps
Cobbaert et al. Different effects of Intralipid and triacylglycerol rich lipoproteins on Kodak Ektachem serum cholesterol determination
EP0615128B1 (fr) Equipement et test pour déterminer un antigène ou un anticorps dans un échantillon
Swinne et al. Detection of circulating capsular polysaccharide antigen from Cryptococcus neoformans
Freudenrich et al. The effects of adrenalectomy on the alpha-adrenergic regulation of cytosolic free calcium in hepatocytes.
Edelman et al. Evaluation of the new Beckman electrophoretic method for CK-MB: comparison with ion exchange chromatography and investigation of a reference outpatient population
Hoffmann et al. Serological distance coefficients

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20081229